IL-6 inhibitors, such as tocilizumab, have been shown to inhibit hepcidin proliferation and improve anemia in inflammatory autoimmune diseases including rheumatoid arthritis and Castleman disease. This evidence concerns the gene IL6 and rheumatoid arthritis.